RankAlpha logo
Back to Rankings

ZNTL

ZentalisB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
A credible October survival presentation could strengthen confidence ahead of the decisive 2027 Part 2 readout. The company reported $174.6 million of cash and marketable securities at June 30 and subsequently closed an offering of 26.45 million shares for approximately $92.6 million in gross proceeds.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +13.4.
What can break
ASPENOVA Phase 3 execution and companion-diagnostic development add cost and regulatory risk.
Momentum
9
Value
41
Sentiment
81
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.40 · Bull $5.50 · Bear $0.65Analysis 2026-10-18; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-18 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-23

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions

Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $7.80
Why
Momentum9 · Δ7d -4.5
Value41 · Δ7d -0.1
Sentiment81 · Δ7d +13.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • Sentiment remains the lead driver in the composite, 7D delta +13.4.

Contradictions & invalidation

  • • ASPENOVA Phase 3 execution and companion-diagnostic development add cost and regulatory risk.
  • • DENALI Part 2 efficacy, durability and safety may not support accelerated approval; the FDA's pathway acknowledgment was conditional.
  • • The investment case depends heavily on azenosertib.

Catalyst clock

2026-10-23

DENALI Part 1b survival presentation at ESMO

Lead driver: Sentiment · See AI snapshot
Momentum
9
8% active weight
Current posture
7d trendFlat
Δ7d
-4.5
Δ21d
-0.6
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
81
45% active weight
Current posture
7d trendImproving
Δ7d
+13.4
Δ21d
+24.7
Why this grade

Composite grade B. Momentum 9.1 / Value 40.6 / Sentiment 80.8

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-18. Scenario method

B+
Bull case
25%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
Most likely
B
Base case
50%
Probability
Target price
$2.40
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$0.65
Analysis reference price unavailable
Analysis 2026-10-18 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$209.23M
Beta
1.71
Shares Out
94.67M
P/E (TTM) · Derived
-1.2
P/S (TTM)
3.68
P/FCF (TTM) · Derived
-1.23
Rev YoY
-100.0%
EPS YoY
+58.8%
Gross Margin
+96.7%
Op Margin
-615.2%
Net Debt
-$206.32M
Current Ratio
4.82
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data